Background: Methylnaltrexone (MNTX) is a peripherally acting µ-opioid receptor antagonist indicated for opioid-induced constipation (OIC). We evaluated whether baseline use of laxatives, including stimulants, osmotic agents, stool softeners, or combinations thereof affects the efficacy and safety of MNTX. Methods: This post hoc analysis included pooled data from 2 multicenter, randomized, double-blind, placebo (PBO)-controlled, institutional review […]

Case Presentation: A 55-year-old man with a past medical history of poorly controlled diabetes and remote intravenous drug use was evaluated for a right chest wall infection. 1 week prior to presentation, he had chest wall erythema, pain resulting in decreased range of motion, fevers, chills, decreased appetite, and weight loss. He presented to an […]

Case Presentation: Discussion45-year-old male with history of HIV on Antiretroviral and treated syphilis presented with painful oral lesions and difficulty swallowing which started several days after being placed on Nitazoxanide, Doxycycline, Levaquin, and Omeprazole for diagnosis of Helicobacter Pylori via Endoscopy done for diarrhea. He was given fluconazole for presumed thrush during ER visit. His […]

Background: Opioid analgesia is an important treatment modality for patients with chronic pain, including pain attributed to cancer- and noncancer-related illness. Unfortunately, an estimated 40%–80% of opioid users experience opioid-induced constipation (OIC). Methylnaltrexone (MNTX) is indicated for the treatment of OIC. In clinical trials, the most common adverse events (AEs) were gastrointestinal (GI) in nature. […]